StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.12 | $1.04 | -7.14% | 1.9M |
| 05-12 | $1.02 | $1.01 | -0.98% | 1.4M |
| 05-13 | $1.06 | $1.12 | +5.66% | 2.9M |
| 05-14 | $1.18 | $1.19 | +0.85% | 2.3M |
| 05-15 | $1.16 | $1.16 | +0.00% | 1.1M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Finnhub hasn't published the next scheduled earnings date yet. The list typically populates 4–8 weeks before the call.
No sell-side coverage available for SLQT.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for SLQT.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.30B | $865.91M | $328.81M | $1.53B |
Operating Income | $70.49M | $34.56M | $-40.75M | $68.50M |
Net Income | $79.03M | $38.83M | $-30.46M | $47.58M |
EPS (Diluted) | $0.11 | $0.01 | $-0.26 | $0.01 |
Total Assets | $1.33B | $1.35B | $1.21B | $1.25B |
Total Liabilities | $671.22M | $732.62M | $660.05M | $673.84M |
Cash & Equivalents | $29.81M | $18.32M | $10.74M | $32.40M |
Free Cash Flow OCF − CapEx | $32.11M | $-23.72M | $-22.68M | $-13.86M |
Shares Outstanding | 176.35M | 176.28M | 175.95M | 172.82M |
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
SLQT is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1138-name primary list.
DNA analysis is not available for this ticker.